Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference

医学 协商一致会议 投票 前列腺癌 德尔菲法 前列腺特异性抗原 梅德林 复发性前列腺癌 家庭医学 肿瘤科 德尔菲 重症监护医学 内科学 多学科方法 循证医学 前列腺 医学物理学 临床实习 批准投票 生化复发 疾病 妇科 患者参与 临床试验
作者
Silke Gillessen,Fabio Turco,Ian D. Davis,Jason Alexander Efstathiou,Louise Emmett,Karim S. Fizazi,Nicholas David James,Neal D. Shore,Eric Jay Small,Matthew Smith,Christopher J. Sweeney,Bertrand F. TOMBAL,Jochen Christoph Walz,Thomas Zilli,Hui-Ming Lin,Martino Pedrani,Marialuisa Puglisi,Vérane Achard,Neeraj Agarwal,Rahul Aggarwal
出处
期刊:European Urology [Elsevier BV]
标识
DOI:10.1016/j.eururo.2026.09.027
摘要

BACKGROUND: Innovations have improved outcomes in high-risk localised, locally advanced, and biochemically recurrent prostate cancer (PC), yet high-level evidence remains limited for many management decisions. The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed an international panel on key clinical questions to complement evidence-based guidelines. OBJECTIVE: Here we present the voting results for the questions on high-risk localised, locally advanced, and biochemically recurrent PC from APCCC 2026. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a multidisciplinary panel of 144 international PC experts used a modified Delphi process to develop 313 multiple-choice consensus questions, of which 134 covered high-risk localised and locally advanced PC, including prostate-specific antigen (PSA) persistence and PSA recurrence, and side effects of treatment. These questions were administered to the 133 voting panel members "panellists" via a web-based survey prior to the conference. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined a priori as ≥75% agreement, with strong consensus defined as ≥90% agreement. Overall, consensus was reached for 44 of the 134 questions (32.8%), with seven questions reaching a strong consensus. Results and limitations The voting results show varying degrees of consensus, as discussed in this article and as detailed in the Supplementary Material. An interactive heat map for the questions can be found at https://apccc.org/APCCC2026-votings-localised-and-locally-advanced-prostate-cancer/. These findings do not include a formal literature review or meta-analysis. CONCLUSIONS: The voting results can help physicians and patients navigate controversial areas of clinical management for which evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Importantly, APCCC 2026 once again identified important gaps (areas of no consensus) that merit evaluation in specifically designed trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蜜蜂完成签到,获得积分10
刚刚
在水一方的应助被喝口可乐采纳,获得30
刚刚
LW3366发布了新的文献求助10
1秒前
马亚斌发布了新的文献求助10
1秒前
秋风的应助被芒果彩虹猪采纳,获得20
2秒前
GPTea的应助被jean采纳,获得20
2秒前
applennad完成签到,获得积分10
2秒前
3秒前
4秒前
4秒前
努力搬砖的小胡完成签到,获得积分10
5秒前
稳重的元瑶完成签到,获得积分10
5秒前
马亚斌完成签到,获得积分20
6秒前
瓦松完成签到,获得积分20
7秒前
等风归完成签到,获得积分10
7秒前
云朝完成签到,获得积分10
8秒前
9秒前
9秒前
ZeKaWa的应助被liu采纳,获得10
9秒前
PEACE完成签到 ,获得积分20
9秒前
儒雅黑猫完成签到 ,获得积分10
9秒前
10秒前
思恩Shen发布了新的文献求助10
10秒前
秦风完成签到,获得积分10
11秒前
杜欣悦发布了新的文献求助10
11秒前
香蕉觅云的应助被顺利毕业mpa采纳,获得10
11秒前
94完成签到,获得积分10
11秒前
fighting完成签到,获得积分10
12秒前
13秒前
13秒前
哈47发布了新的文献求助10
14秒前
俭朴含卉完成签到 ,获得积分10
14秒前
饼饼完成签到,获得积分20
14秒前
虚幻明杰完成签到,获得积分10
14秒前
Johnny发布了新的文献求助10
15秒前
wxz1998完成签到,获得积分10
15秒前
O基米德发布了新的文献求助10
15秒前
16秒前
田様的应助被木头采纳,获得10
16秒前
吱哦周完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621